Pharmaceutical

Cytori Therapeutics (NASDAQ:CYTX) announced that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy for men with stress urinary incontinence as a complication of prostate intervention.  A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial. As quoted in the press release: The …

Cytori Therapeutics (NASDAQ:CYTX) announced that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy for men with stress urinary incontinence as a complication of prostate intervention.  A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial.

As quoted in the press release:

The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) at 52 weeks after treatment. A number of other key secondary endpoints are also being assessed. If the primary endpoint is successfully achieved, the data may be used to seek approval of ECCI-50 for this indication.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1809.91-0.13
Silver19.89+0.03
Copper3.61-0.10
Palladium1965.07+9.98
Platinum891.26+2.98
Oil108.46+2.70
Heating Oil3.96+0.13
Natural Gas5.620.00

DOWNLOAD FREE REPORTS

×